文献速递肿瘤 PET/CT

定量评估病灶反应异质性以实现更优的临床结局预测

Quantitative evaluation of lesion response heterogeneity for superior prognostication of clinical outcome.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-05-31

本研究回顾性纳入241例患者(127例弥漫大B细胞淋巴瘤和114例非小细胞肺癌)的基线和治疗中或放化疗后[18F]FDG PET/CT,用自动化软件量化所有可疑病灶感兴趣区的变化,多变量Cox模型显示量化所有病灶反应异质性对总生存的预测能力优于RECIST、PERCIST和Deauville评分。

要点

  • 量化所有病灶反应异质性的Cox模型在DLBCL中预测OS的C-index为0.84(p<0.001),在NSCLC中为0.71(p<0.001)。
  • 使用病灶ROI子集或排除反应异质性特征后预测能力显著下降(p<0.001)。
  • RECIST、PERCIST和Deauville评分与OS无显著关联(C-index<0.65且p>0.1)。

核心结论

  • 定量评估所有个体病灶的反应异质性对于更优地预测临床结局是必要的。

研究设计与样本

  • 回顾性获取241例患者的[18F]FDG PET/CT扫描,其中127例弥漫大B细胞淋巴瘤(DLBCL)和114例非小细胞肺癌(NSCLC),扫描时间为基线和化疗期间或放化疗后。
  • 使用自动化TRAQinform IQ软件(AIQ Solutions)分析图像,量化可疑癌症感兴趣区(病灶ROI)的变化。
  • 训练多变量Cox比例风险模型以预测总生存(OS),使用不同的定量特征集和病灶ROI组合,通过自助法以C-index和t检验进行比较。
  • 将最佳拟合模型与RECIST、PERCIST和Deauville评分的自动化版本进行比较。

主要发现

  • 在DLBCL中,使用量化所有个体病灶ROI反应异质性的特征训练的多变量CoxPH模型C-index为0.84(p<0.001)。
  • 在NSCLC中,使用量化所有个体病灶ROI反应异质性的特征训练的多变量CoxPH模型C-index为0.71(p<0.001)。
  • 使用病灶ROI子集时预测能力显著下降(p<0.001),DLBCL的C-index为0.78,NSCLC的C-index为0.67。
  • 排除反应异质性特征时预测能力显著下降(p<0.001),DLBCL的C-index为0.67,NSCLC的C-index为0.70。
  • RECIST、PERCIST和Deauville评分与OS无显著关联(C-index<0.65且p>0.1),性能显著劣于多变量模型(p<0.001)。

局限性

  • 本研究为回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Standardized reporting of treatment response in oncology patients has traditionally relied on methods like RECIST, PERCIST and Deauville score. These endpoints assess only a few lesions, potentially overlooking the response heterogeneity of all disease. This study hypothesizes that comprehensive spatial-temporal evaluation of all individual lesions is necessary for superior prognostication of clinical outcome. METHODS: [18F]FDG PET/CT scans from 241 patients (127 diffuse large B-cell lymphoma (DLBCL) and 114 non-small cell lung cancer (NSCLC)) were retrospectively obtained at baseline and either during chemotherapy or post-chemoradiotherapy. An automated TRAQinform IQ software (AIQ Solutions) analyzed the images, performing quantification of change in regions of interest suspicious of cancer (lesion-ROI). Multivariable Cox proportional hazards (CoxPH) models were trained to predict overall survival (OS) with varied sets of quantitative features and lesion-ROI, compared by bootstrapping with C-index and t-tests. The best-fit model was compared to automated versions of previously established methods like RECIST, PERCIST and Deauville score. RESULTS: Multivariable CoxPH models demonstrated superior prognostic power when trained with features quantifying response heterogeneity in all individual lesion-ROI in DLBCL (C-index = 0.84, p < 0.001) and NSCLC (C-index = 0.71, p < 0.001). Prognostic power significantly deteriorated (p < 0.001) when using subsets of lesion-ROI (C-index = 0.78 and 0.67 for DLBCL and NSCLC, respectively) or excluding response heterogeneity (C-index = 0.67 and 0.70). RECIST, PERCIST, and Deauville score could not significantly associate with OS (C-index < 0.65 and p > 0.1), performing significantly worse than the multivariable models (p < 0.001). CONCLUSIONS: Quantitative evaluation of response heterogeneity of all individual lesions is necessary for the superior prognostication of clinical outcome.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lokre O, Perk TG, Weisman AJ, et al. Quantitative evaluation of lesion response heterogeneity for superior prognostication of clinical outcome. Eur J Nucl Med Mol Imaging. 2024. PMID: 38819668. doi:10.1007/s00259-024-06764-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。